↓ Skip to main content

Measles

Overview of attention for book
Attention for Chapter 11: Measles virus for cancer therapy
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#3 of 587)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
5 news outlets
twitter
149 tweeters
facebook
38 Facebook pages
googleplus
3 Google+ users
video
3 video uploaders

Readers on

mendeley
87 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Measles virus for cancer therapy
Chapter number 11
Book title
Measles
Published in
Current topics in microbiology and immunology, February 2009
DOI 10.1007/978-3-540-70617-5_11
Pubmed ID
Book ISBNs
978-3-54-070616-8, 978-3-54-070617-5
Authors

Russell SJ, Peng KW, Stephen J. Russell, Kah Whye Peng, S. J. Russell, K. W. Peng

Abstract

Measles virus offers an ideal platform from which to build a new generation of safe, effective oncolytic viruses. Occasional so-called spontaneous tumor regressions have occurred during natural measles infections, but common tumors do not express SLAM, the wild-type MV receptor, and are therefore not susceptible to the virus. Serendipitously, attenuated vaccine strains of measles virus have adapted to use CD46, a regulator of complement activation that is expressed in higher abundance on human tumor cells than on their nontransformed counterparts. For this reason, attenuated measles viruses are potent and selective oncolytic agents showing impressive antitumor activity in mouse xenograft models. The viruses can be engineered to enhance their tumor specificity, increase their antitumor potency, and facilitate noninvasive in vivo monitoring of their spread. A major impediment to the successful deployment of oncolytic measles viruses as anticancer agents is the high prevalence of preexisting anti-measles immunity, which impedes bloodstream delivery and curtails intratumoral virus spread. It is hoped that these problems can be addressed by delivering the virus inside measles-infected cell carriers and/or by concomitant administration of immunosuppressive drugs. From a safety perspective, population immunity provides an excellent defense against measles spread from patient to carers and, in 50 years of human experience, reversion of attenuated measles to a wild-type pathogenic phenotype has not been observed. Clinical trials testing oncolytic measles viruses as an experimental cancer therapy are currently underway.

Twitter Demographics

The data shown below were collected from the profiles of 149 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Malaysia 1 1%
Turkey 1 1%
Germany 1 1%
Unknown 84 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 22 25%
Student > Bachelor 18 21%
Student > Ph. D. Student 16 18%
Researcher 8 9%
Student > Doctoral Student 5 6%
Other 9 10%
Unknown 9 10%
Readers by discipline Count As %
Agricultural and Biological Sciences 20 23%
Biochemistry, Genetics and Molecular Biology 20 23%
Medicine and Dentistry 16 18%
Immunology and Microbiology 7 8%
Chemistry 3 3%
Other 10 11%
Unknown 11 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 173. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 October 2020.
All research outputs
#112,630
of 16,050,526 outputs
Outputs from Current topics in microbiology and immunology
#3
of 587 outputs
Outputs of similar age
#662
of 136,414 outputs
Outputs of similar age from Current topics in microbiology and immunology
#1
of 9 outputs
Altmetric has tracked 16,050,526 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 587 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 136,414 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them